Lunn CA - Search Results

1

Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336.

Gonsiorek W, Hesk D, Chen SC, Kinsley D, Fine JS, Jackson JV, Bober LA, Deno G, Bian H, Fossetta J, Lunn CA, Kozlowski JA, Lavey B, Piwinski J, Narula SK, Lundell DJ, Hipkin RW. Gonsiorek W, et al. Among authors: lunn ca. J Biol Chem. 2006 Sep 22;281(38):28143-51. doi: 10.1074/jbc.M602364200. Epub 2006 Jun 5. J Biol Chem. 2006. PMID: 16754676 Free article.

2

Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.

Lavey BJ, Kozlowski JA, Hipkin RW, Gonsiorek W, Lundell DJ, Piwinski JJ, Narula S, Lunn CA. Lavey BJ, et al. Among authors: lunn ca. Bioorg Med Chem Lett. 2005 Feb 1;15(3):783-6. doi: 10.1016/j.bmcl.2004.11.007. Bioorg Med Chem Lett. 2005. PMID: 15664857

3

Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies.

Shankar BB, Lavey BJ, Zhou G, Spitler JA, Tong L, Rizvi R, Yang DY, Wolin R, Kozlowski JA, Shih NY, Wu J, Hipkin RW, Gonsiorek W, Lunn CA. Shankar BB, et al. Among authors: lunn ca. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4417-20. doi: 10.1016/j.bmcl.2005.07.023. Bioorg Med Chem Lett. 2005. PMID: 16115769

4

A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.

Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA. Lunn CA, et al. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. doi: 10.1124/jpet.105.093500. Epub 2005 Oct 28. J Pharmacol Exp Ther. 2006. PMID: 16258021

5

Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate.

Fossetta J, Deno G, Gonsiorek W, Fan X, Lavey B, Das P, Lunn C, Zavodny PJ, Lundell D, Hipkin RW. Fossetta J, et al. Br J Pharmacol. 2004 Jul;142(5):851-60. doi: 10.1038/sj.bjp.0705856. Epub 2004 Jun 14. Br J Pharmacol. 2004. PMID: 15197107 Free PMC article.

6

Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.

Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Gonsiorek W, et al. Mol Pharmacol. 2000 May;57(5):1045-50. Mol Pharmacol. 2000. PMID: 10779390

7

Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates.

Gonsiorek W, Lunn CA, Fan X, Deno G, Kozlowski J, Hipkin RW. Gonsiorek W, et al. Among authors: lunn ca. Br J Pharmacol. 2007 Aug;151(8):1262-71. doi: 10.1038/sj.bjp.0707336. Epub 2007 Jul 2. Br J Pharmacol. 2007. PMID: 17603556 Free PMC article.

8

Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.

Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L. Lunn CA, et al. Br J Pharmacol. 2008 Jan;153(2):226-39. doi: 10.1038/sj.bjp.0707480. Epub 2007 Oct 1. Br J Pharmacol. 2008. PMID: 17906679 Free PMC article. Review.

9

Targeting the CB2 receptor for immune modulation.

Lunn CA, Reich EP, Bober L. Lunn CA, et al. Expert Opin Ther Targets. 2006 Oct;10(5):653-63. doi: 10.1517/14728222.10.5.653. Expert Opin Ther Targets. 2006. PMID: 16981823 Review.

10

Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands.

Lavey BJ, Kozlowski JA, Shankar BB, Spitler JM, Zhou G, Yang DY, Shu Y, Wong MK, Wong SC, Shih NY, Wu J, McCombie SW, Rizvi R, Wolin RL, Lunn CA. Lavey BJ, et al. Among authors: lunn ca. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3760-4. doi: 10.1016/j.bmcl.2007.04.028. Epub 2007 Apr 10. Bioorg Med Chem Lett. 2007. PMID: 17466519

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page